Evidence mapPaperPMID 37138848Full record

ArticleFrontiers in pharmacology2023

Khaidem Devika Chanu, Nanaocha Sharma, Vimi Kshetrimayum, Sushil Kumar Chaudhary, Suparna Ghosh, Pallab Kanti Haldar, Pulok K Mukherjee

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Cytotoxic and Antimicrobial Activity of theMolecules (Basel, Switzerland) · 2025
    Review
  2. Article
  3. Frontiers in veterinary science · 2025
    Article
  4. Article
  5. Review
  6. Heliyon · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Khaidem Devika ChanuInstitute of Bio-resources and Sustainable Development (IBSD), Imphal, Manipur, India.
Nanaocha SharmaInstitute of Bio-resources and Sustainable Development (IBSD), Imphal, Manipur, India.
Vimi KshetrimayumInstitute of Bio-resources and Sustainable Development (IBSD), Imphal, Manipur, India.
Sushil Kumar ChaudharyInstitute of Bio-resources and Sustainable Development (IBSD), Imphal, Manipur, India.
Suparna GhoshSchool of Natural Product Studies, Department of Pharmaceutical Technology, Jadavpur University (JU), Kolkata, West Bengal, India.
Pallab Kanti HaldarSchool of Natural Product Studies, Department of Pharmaceutical Technology, Jadavpur University (JU), Kolkata, West Bengal, India.
Pulok K MukherjeeInstitute of Bio-resources and Sustainable Development (IBSD), Imphal, Manipur, India.
Institute of Bio-Resources and Sustainable Development · INJadavpur University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes has become one of the major health concerns of the 21st century, marked by hyperglycemia or glycosuria, and is associated with the development of several secondary health complications. Due to the fact that chemically synthesized drugs lead to several inevitable side effects, new antidiabetic medications from plants have gained substantial attention. Thus, the current study aims to evaluate the antidiabetic capacity of the

Indexed as

Ageratina adenophoraantidiabetic activitycaffeic acidchlorogenic acidstreptozotocin–nicotinamidetype 2 diabetes

Identifiers

PMID37138848
PMCPMC10149788
OpenAlexW4366207686

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.